What is NOWDiagnostics?
NOWDiagnostics, Inc. operates at the forefront of the medical diagnostics industry, specializing in rapid, lab-quality testing solutions. Its flagship ADEXUSDx platform utilizes a single drop of blood to identify a wide array of conditions, effectively eliminating the logistical bottlenecks associated with traditional off-site laboratory processing. By providing actionable data in minutes rather than days, the company addresses a critical market demand for efficiency in clinical decision-making and patient management. The firm's technology is engineered to integrate seamlessly into diverse healthcare environments, from primary care clinics to emergency departments, thereby enhancing the speed and accuracy of diagnostic workflows.
How much funding has NOWDiagnostics raised?
NOWDiagnostics has raised a total of $33.4M across 2 funding rounds:
Debt
$10.9M
Series B
$22.5M
Debt (2016): $10.9M, investors not publicly disclosed
Series B (2024): $22.5M led by Labcorp venture fund, Kompass Kapital Management, and DigitalDx Ventures
Key Investors in NOWDiagnostics
Labcorp venture fund
The venture arm of a global life sciences leader, focusing on strategic investments in diagnostic technologies and healthcare services that enhance laboratory efficiency.
Kompass Kapital Management
A private equity group with a diversified investment portfolio, utilizing conservative underwriting standards to support value-driven growth across various business sectors.
DigitalDx Ventures
A venture firm specializing in the intersection of artificial intelligence and healthcare, targeting game-changing technologies that improve clinical outcomes.
What's next for NOWDiagnostics?
With the successful closure of this major enterprise-level funding, NOWDiagnostics is well-positioned to accelerate its commercialization strategy and broaden its diagnostic menu. The strategic alignment with key industry investors suggests a focus on scaling manufacturing capabilities and potentially exploring new clinical applications for its finger-prick technology. As the healthcare sector increasingly prioritizes decentralized care models, the company's ability to deliver lab-grade results at the point of care provides a distinct competitive advantage. Future growth will likely center on expanding market penetration, strengthening regulatory pathways for new assays, and leveraging data-driven insights to further optimize the ADEXUSDx ecosystem for global healthcare providers.
See full NOWDiagnostics company page
